Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies
Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …
Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment
J Remon, B Besse - Frontiers in Oncology, 2018 - frontiersin.org
Brain metastases (BM) are common in non-small cell lung cancer patients including in
molecularly selected populations, such as EGFR-mutant and ALK-rearranged tumors. They …
molecularly selected populations, such as EGFR-mutant and ALK-rearranged tumors. They …
Integration of systemic therapy and stereotactic radiosurgery for brain metastases
Simple Summary In the multi-modal treatment of brain metastasis (BM), the role of systemic
therapy has undergone a recent revolution. Due to the development of multiple agents with …
therapy has undergone a recent revolution. Due to the development of multiple agents with …
[HTML][HTML] Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of …
B Zhao, Y Wang, Y Wang, W Chen, L Zhou… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
Preferable treatments for epidermal growth factor receptor (EGFR)-mutant non-small cell
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …
Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: a meta-analysis
C Wang, X Lu, Z Lyu, N Bi, L Wang - Lung Cancer, 2018 - Elsevier
Abstract Objective About 50–70% non-small cell lung cancer (NSCLC) patients with EGFR
mutation go through brain metastases (BM). Radiotherapy is the standard treatment before …
mutation go through brain metastases (BM). Radiotherapy is the standard treatment before …
Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review
PY Borius, J Régis, A Carpentier… - Cancer and Metastasis …, 2021 - Springer
Stereotactic radiosurgery (SRS) is a standard option for brain metastases (BM). There is lack
of consensus when patients have a systemic treatment, if a washout is necessary. The aim of …
of consensus when patients have a systemic treatment, if a washout is necessary. The aim of …
[HTML][HTML] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
K Dong, W Liang, S Zhao, M Guo, Q He… - Translational Lung …, 2019 - ncbi.nlm.nih.gov
Background It has been confirmed that epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and …
Y Song, S Lin, J Chen, J Dang - BMC cancer, 2023 - Springer
Background It remains uncertain whether first-line treatment with upfront brain radiotherapy
(RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …
(RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …
Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC)
N Andratschke, J Kraft, C Nieder, R Tay, R Califano… - Lung Cancer, 2019 - Elsevier
Brain metastases are common events in the natural course of many advanced solid cancers
like breast, lung and renal cancer or melanoma with a cumulative risk of 10–30% in adults …
like breast, lung and renal cancer or melanoma with a cumulative risk of 10–30% in adults …